T1	PROC 87 168	Estudio adaptativo de fase 2/3, aleatorizado, doble ciego, controlado con placebo
T2	DISO 56 64	COVID-19
#1	AnnotatorNotes T2	C5203670; COVID19 (disease); Disease or Syndrome
T3	PROC 174 208	evaluar la eficacia y la seguridad
#2	AnnotatorNotes T3	C0511730; Identify product efficacy and safety issues; Health Care Activity
T4	PROC 235 249	hospitalizados
#3	AnnotatorNotes T4	C0019993; Hospitalization; Health Care Activity
T5	DISO 285 310	Infección por coronavirus
#4	AnnotatorNotes T5	C5203670; COVID19 (disease); Disease or Syndrome
T6	DISO 371 381	enfermedad
#5	AnnotatorNotes T6	C0012634; Disease; Disease or Syndrome
T7	DISO 389 423	disfunción orgánica multisistémica
T8	DISO 426 444	enfermedad crítica
T9	DISO 446 470	Infección por SARS-CoV-2
#6	AnnotatorNotes T9	C5203670; COVID19 (disease); Disease or Syndrome
T10	DISO 254 261	COVID19
#7	AnnotatorNotes T10	C5203670; COVID19 (disease); Disease or Syndrome
T11	DISO 843 851	COVID-19
#8	AnnotatorNotes T11	C5203670; COVID19 (disease); Disease or Syndrome
T12	PROC 582 614	recuento absoluto de neutrófilos
#9	AnnotatorNotes T12	C0948762; Absolute neutrophil count; Laboratory Procedure
T13	PROC 616 619	RAN
#10	AnnotatorNotes T13	C0948762; Absolute neutrophil count; Laboratory Procedure
T14	CHEM 212 221	sarilumab
#11	AnnotatorNotes T14	C3885145; sarilumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T15	PROC 679 688	plaquetas
#12	AnnotatorNotes T15	C0032181; Platelet Count measurement; Laboratory Procedure
T16	PROC 732 761	tratamientos inmunodepresores
T17	CHEM 780 796	corticosteroides
#13	AnnotatorNotes T17	C0001617; Adrenal Cortex Hormones; Hormone · Organic Chemical · Pharmacologic Substance
T18	DISO 813 823	enfermedad
#14	AnnotatorNotes T18	C0012634; Disease; Disease or Syndrome
T19	DISO 868 908	enfermedades autoinmunes o inflamatorias
T20	DISO 962 974	tuberculosis
#15	AnnotatorNotes T20	C0041296; Tuberculosis; Disease or Syndrome
T21	DISO 989 1034	infecciones bacterianas o fúngicas sistémicas
T22	CHEM 46 55	Sarilumab
#16	AnnotatorNotes T22	C3885145; sarilumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T23	ANAT 603 614	neutrófilos
#17	AnnotatorNotes T23	C0027950; neutrophil; Cell
T24	PROC 642 645	AST
#18	AnnotatorNotes T24	C0201899; Aspartate aminotransferase measurement; Laboratory Procedure
T25	PROC 648 651	ALT
#19	AnnotatorNotes T25	C0201836; Alanine aminotransferase measurement; Laboratory Procedure
T26	CHEM 745 761	inmunodepresores
#20	AnnotatorNotes T26	C0021081; Immunosuppressive Agents; Immunologic Factor · Pharmacologic Substance
T27	Date 13 17	2020
T28	LIVB 225 234	pacientes
#21	AnnotatorNotes T28	C0030705; Patients; Patient or Disabled Group
T29	LIVB 299 310	coronavirus
#22	AnnotatorNotes T29	C5203676; SARS-CoV-2; Virus
T32	Duration 552 562	> 48 horas
T33	Route 797 803	orales
#23	AnnotatorNotes T33	C1527415; Oral Route of Drug administration; Functional Concept
T35	Date 909 916	pasadas
T36	Date 919 927	actuales
T37	Spec_cue 937 947	sospechada
T38	LIVB 975 984	Pacientes
#24	AnnotatorNotes T38	C0030705; Patients; Patient or Disabled Group
T39	LIVB 1015 1023	fúngicas
#25	AnnotatorNotes T39	C0016832; Fungi; Fungus
T40	Spec_cue 1043 1054	sospechadas
T43	LIVB 1001 1012	bacterianas
#26	AnnotatorNotes T43	C0004611; Bacteria; Bacterium
T30	LIVB 341 354	participantes
#27	AnnotatorNotes T30	C4554048; Study Participant; Population Group
T31	LIVB 460 470	SARS-CoV-2
#28	AnnotatorNotes T31	C5203676; SARS-CoV-2; Virus
T34	Neg_cue 824 826	no
A1	Assertion T20 Speculated
A2	Assertion T21 Speculated
A3	Status T16 History_of
A4	Status T19 History_of
A5	Status T20 History_of
A6	Assertion T11 Negated
#29	AnnotatorNotes T16	C0021079; Therapeutic immunosuppression; Therapeutic or Preventive Procedure
#30	AnnotatorNotes T19	C0004364; Autoimmune Diseases; Disease or Syndrome + C1290884; Inflammatory disorder; Disease or Syndrome
R1	Experiences Arg1:T28 Arg2:T14	
R4	Experiences Arg1:T28 Arg2:T10	
R5	Causes Arg1:T29 Arg2:T5	
R6	Experiences Arg1:T30 Arg2:T6	
T41	Quantifier_or_Qualifier 382 387	grave
R7	Has_Quantifier_or_Qualifier Arg1:T6 Arg2:T41	
R8	Experiences Arg1:T30 Arg2:T7	
R9	Experiences Arg1:T30 Arg2:T8	
R10	Causes Arg1:T31 Arg2:T9	
T44	Observation 542 551	sobreviva
R12	Has_Duration_or_Interval Arg1:T44 Arg2:T32	
T45	Spec_cue 524 537	Poco probable
R13	Speculation Arg1:T45 Arg2:T44	
A7	Assertion T44 Speculated
T46	PROC 572 581	selección
#31	AnnotatorNotes T46	C0242802; Patient Selection; Research Activity
R15	Before Arg1:T46 Arg2:T44	
T47	Result_or_Value 621 640	inferior a 2000/mm3
R14	Has_Result_or_Value Arg1:T12 Arg2:T47	
R16	Has_Result_or_Value Arg1:T13 Arg2:T47	
T48	Result_or_Value 652 677	superior a 5 veces el LSN
R17	Has_Result_or_Value Arg1:T25 Arg2:T48	
R18	Has_Result_or_Value Arg1:T24 Arg2:T48	
T49	Result_or_Value 689 705	< 50 000 por mm3
R19	Has_Result_or_Value Arg1:T15 Arg2:T49	
R20	Used_for Arg1:T26 Arg2:T16	
T50	Observation 762 796	Uso prolongado de corticosteroides
R21	Has_Route_or_Mode Arg1:T17 Arg2:T33	
R22	Negation Arg1:T34 Arg2:T11	
R24	Overlap Arg1:T50 Arg2:T18	
R25	Overlap Arg1:T19 Arg2:T35	
R26	Overlap Arg1:T19 Arg2:T36	
R27	Speculation Arg1:T37 Arg2:T20	
R28	Experiences Arg1:T38 Arg2:T21	
R29	Speculation Arg1:T40 Arg2:T21	
R30	Causes Arg1:T39 Arg2:T21	
R31	Causes Arg1:T43 Arg2:T21	
T51	Quantifier_or_Qualifier 1035 1042	activas
R32	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T51	
#32	AnnotatorNotes T51	C0679217; Active State; Idea or Concept
A8	Status T26 History_of
#33	AnnotatorNotes T35	C1444637; In the past; Temporal Concept
#34	AnnotatorNotes T36	C0521116; Current (present time); Temporal Concept
#35	AnnotatorNotes T1	C3274373; Adaptive Design; Research Activity + C0282460; Phase 2 Clinical Trials; Research Activity + C0282461; Phase 3 Clinical Trials; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity + C0599724; placebo controlled study; Research Activity · Intellectual Product
#36	AnnotatorNotes T7	C0026766; Multiple Organ Failure; Pathologic Function
#37	AnnotatorNotes T8	C0010340; Critical Illness; Disease or Syndrome
R23	Overlap Arg1:T18 Arg2:T11	
R2	Experiences Arg1:T28 Arg2:T4	
#38	AnnotatorNotes T41	C1547227; Severe - Severity of Illness Code; Intellectual Product
#39	AnnotatorNotes T21	C4285778; Systemic bacterial infection; Disease or Syndrome | C0553576; Systemic mycosis; Disease or Syndrome
A9	Experiencer T38 Patient
A10	Experiencer T30 Patient
A11	Experiencer T28 Patient
